

**French National Guidelines for the Appropriate Use of Opioids: Analgesia, Opioid Use Disorder,
and Overdose Prevention – Part 2: Prevention and Management of Opioid Use Disorder and
Overdose**

Célian BERTIN (M.D; Ph.D.)*^{1,2}, Julie DUPOUY (M.D; Ph.D.)^{3,4}, Nicolas AUTHIER (M.D;
Pharm.D; Ph.D.)^{1,2}, Nathalie. MICHENOT (M.D.)⁵, Sidonie VERDIER (M.D.)⁶, Mathieu CHAPPUY
(Pharm.D;Ph.D.)⁷, Anne-Priscille TROUVIN (M.D; Ph.D.)⁸

1 : Université Clermont Auvergne, UMR Inserm 1107-Neuro-Dol, Clermont-Ferrand, France

2 : CHU Clermont-Ferrand, Service de Pharmacologie médicale, Centres Addictovigilance et
Pharmacovigilance, Centre d'Évaluation et Traitement de la Douleur, Clermont-Ferrand, France

3 : Département de Médecine Générale, Université de Toulouse, Toulouse, France

4 : CERPOP, UMR 1295 Université de Toulouse – Inserm, Toulouse, France

5 : Equipe de soins palliatifs, Centre Hospitalier de Versailles, Le Chesnay, France

6 : Equipe Mobile de Soins Palliatifs, Département Interdisciplinaire de Soins de Support pour le
Patient en Oncologie, Centre François Baclesse, Caen, France

7 : Service Universitaire d'Addictologie de Lyon, Groupement Hospitalier Centre, Hospices Civils de
Lyon, Lyon, France. Centre de Soins, d'Accompagnement et de Prévention en Addictologie,
Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France

8 : Université Paris Cité, Paris, France ; Centre d'Evaluation et Traitement de la Douleur, CHU Paris
Centre Cochin, Paris, France ; INSERM U987, Boulogne Billancourt, France

*Corresponding Author: Célian BERTIN (ORCID: 0000-0002-2393-7061)

Address: Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Pharmacologie Médicale,
BP69, 63000 Clermont-Ferrand, FRANCE

E-mail address: cbertin@chu-clermontferrand.fr

Appendices

Appendix 1. Glossary

Addiction: A primary, chronic neurobiological disorder whose development and expression are influenced by genetic, psychosocial, and environmental factors. The clinical concept of addiction is encompassed within the diagnosis of “substance use disorder” and is characterized by behaviors including one or more of the following: impaired control over substance use, compulsive use, continued use despite negative consequences for the individual and/or their environment, and an intense urge or need to use the substance (craving).

Note: Although the term “addiction” remains commonly used in the scientific literature, some contemporary frameworks recommend the use of less stigmatizing terminology, such as “substance use disorder”.

Craving: A clinical concept characterized by an intense and irrepressible desire to consume a substance. The persistence of this strong urge is associated with an increased risk of relapse in substance use disorders.

Misuse: When applied to psychoactive substances, this is a broad clinical concept encompassing most forms of non-compliant use, whether prescribed or not, including in individuals who do not meet criteria for a substance use disorder. When applied to prescribed medications, it refers to any intentional inappropriate use or use other than that for which the medication was prescribed. The term “abuse” is sometimes used with a similar meaning, particularly in the Anglo-Saxon literature, but more specifically refers to non-therapeutic use of a substance.

Opioid use disorder (OUD): A substance use disorder involving opioids as the substance of concern. This dimensional diagnosis was introduced in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). It encompasses the previously distinct categorical concepts of abuse and dependence (“addiction” in earlier editions) and is

characterized by the identification of personal, social, and occupational consequences of repeated to compulsive opioid use.

Physical dependence: A state of adaptation in which a patient's organism has re-established equilibrium around an exogenous substance that is regularly administered, resulting in tolerance. This phenomenon of "pharmacological dependence" becomes evident when the substance is no longer administered regularly and/or in sufficient quantity, leading to a disruption of this equilibrium and the onset of characteristic unpleasant physical and psychological symptoms, known as withdrawal syndrome.

Appendix 2. Detailed implementation modalities

The HAS is the sponsor of these clinical practice guidelines. They represent rigorous syntheses of the state of the art and scientific evidence at a given point in time, as described in the scientific rationale: https://www.has-sante.fr/jcms/p_3326117/fr/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-sur doses-argumentaire. They are not intended to replace the clinician's judgment in the management of individual patients, which should be based on the clinician's own assessment and the patient's preferences.

These guidelines were developed according to the methodology described in the HAS guidance document "*Development of Clinical Practice Guidelines – Method for Clinical Practice Recommendations*" [1]. This is the preferred method at HAS, due to its scientific rigor.

In summary, the process is based on:

- The involvement of healthcare professionals, patients, and users concerned with the topic.

- Transparency regarding the critical appraisal of the literature, the main debates and decisions taken by the working group members, the formal opinions of the reading group members, and the contribution of all participants across the groups.
- Independence in guideline development, given the status of HAS as an independent public authority with a scientific mandate, and the independence of the working and reading groups, as well as financial independence.
- Management and compatibility of interests declared by experts in the working and reading groups, which are public and accessible at <https://dpi.sante.gouv.fr/>. These declarations were assessed using the HAS conflict of interest grid and considered to ensure that no conflicts influenced the process. The declarations of the working group members were deemed compatible with their participation by the HAS Conflict of Interest Committee.

The project was coordinated by an HAS project manager, who attended all meetings, ensured compliance with the methodology, and oversaw the quality of the literature review. The project manager also coordinated and organized the logistics, ensured that the group composition complied with the scope set in the initial framework document, and guaranteed that the diversity of professional backgrounds, perspectives, and practice settings was represented.

Working group

A multidisciplinary and multiprofessional working group was convened by HAS. It included 27 members: healthcare professionals from both public and private sectors, from various regions and schools of thought, representatives of patient and user associations, and representatives of public agencies. The list of professional organizations and patient/user associations invited to nominate individual experts for the working and reading groups is provided in Table S1 in Supplementary files.

A chairperson was appointed by HAS to coordinate the work of the group in collaboration with the project manager.

Six project officers, each responsible for specific sections corresponding to their expertise, were appointed by HAS to identify, select, and analyze the literature, and draft the scientific rationale. They also contributed to drafting the recommendations.

Drafting of the scientific rationale

The drafting of the scientific rationale was based on the critical appraisal and synthesis of the literature, supplemented by the input of the working group.

The literature search was systematic, structured, and hierarchical. The search strategy was developed jointly by the project manager, the working group chair, and the project officers, and executed by an HAS information specialist, to ensure independence. It covered the period from 01/01/2009 to 31/12/2021. The detailed strategy, including combinations of thesaurus and free-text terms, is presented in Table S2 (Supplementary files), while the list of websites consulted (publishing clinical guidelines, health technology assessments, ethical or economic reports, and professional society recommendations) is available in Table S3 (Supplementary files).

Bibliographic selection of references, according to predefined eligibility criteria, was performed by the project officers, the project manager, and the group chair prior to the first steering group meeting. Each selected article was critically appraised, focusing first on study methodology, then results. The level of evidence was determined for each study.

The literature review was restricted to studies on the efficacy or safety of the proposed interventions, after systematic evaluation of methodology. Included publications were:

- Clinical practice guidelines (systematic reviews, multidisciplinary expert opinions, and user representative input) published since 2009.
- Systematic reviews of controlled trials, with or without meta-analysis, published in French or English since 2009.
- Controlled clinical trials (randomized or not), published since 2009 and not already included in systematic reviews on the same topic.

- Cohort or comparative studies published since 2009 and not already included in systematic reviews.

This methodology identified 4,453 references. Due to the abundance of literature, the working group prioritized studies with the highest level of evidence (including well-conducted randomized controlled trials and meta-analyses), while also considering relevant lower-level evidence and expert consensus when necessary. A total of 491 references were analyzed, of which 223 were retained.

Drafting of the initial recommendations

The members of the working group (Table S4, Supplementary files) met six times to draft, based on the scientific rationale and project officer proposals, the initial version of the recommendations submitted to the reading group.

Reading group

The reading group (Table S5, Supplementary files), qualitatively similar in composition to the working group, included 49 healthcare professionals, patient and user representatives, and members from specialties, professions, or sectors not represented in the working group. Seven additional representatives from public agencies with relevant expertise were also consulted.

The reading group provided feedback electronically, including formal ratings and comments on the content and format of the initial draft, particularly regarding applicability and readability. They were also invited to comment on the scientific rationale in whole or in part.

Final recommendations

The ratings and comments from the reading group were analyzed and discussed by the working group, which revised the rationale as needed and finalized the recommendations and summary sheets during three further meetings.

As these guidelines are based solely on Level 1 studies, they were graded “A” according to the HAS evidence grading scale.

Validation by the HAS College and dissemination

The recommendations were then submitted to the HAS College for adoption and subsequently published on www.has-sante.fr in March 2022.

The HAS has authorized their scientific dissemination and publication in peer-reviewed journals, provided that the content remains consistent with the original guideline document.

Table S1. Professional organizations and patient/user associations invited to nominate individual experts

Collège de la pharmacie d'officine et de la pharmacie hospitalière / College of Community and Hospital Pharmacy (CPOPH)*
Association française des soins de support / French Association for Supportive Care in Oncology (AFSOS)*
Société française des soins palliatifs / French Society for Palliative Care (SFAP)*
Société française d'étude et du traitement de la douleur / French Society for the Study and Treatment of Pain (SFETD)*
Fédération addiction / Addiction Federation (FA)*
Fédération française d'addictologie / French Federation of Addictology (FFA)*
CNP de psychiatrie / National Professional Council of Psychiatry (CNPP)*
Fédération française de psychiatrie / French Federation of Psychiatry (FFP)
Collège national pour la qualité des soins en psychiatrie / National College for Quality of Psychiatric Care (CNQSP)
Collège infirmier français / French Nursing College (CIF)
CNP infirmier / National Professional Council of Nursing (CNPI)*
Collège infirmier de puériculture / College of Pediatric Nursing (CIP)*
Conseil national professionnel de chirurgie orthopédique et traumatologique / Société française de chirurgie orthopédique et traumatologique / National Professional Council of Orthopedic and Trauma Surgery / French Society of Orthopedic and Trauma Surgery (CNP-COT / SOFCOT)
Collège de médecine générale / Collège national des enseignants généralistes / College of General Practice / National College of General Practice Teachers (CMG / CNGE)
CNP médecine d'urgence / National Professional Council of Emergency Medicine
Psychoactif / Psychoactif*
Association française vaincre la douleur / French Association Against Pain (AFVD)*
Autosupport des usagers de drogues / Self-Support Association of Drug Users (ASUD)*
France patient expert addiction / France Patient Expert Addiction (FPEA)*
Société française de médecine d'urgence / French Society of Emergency Medicine (SFMU)*
Société nationale française de médecine interne / French National Society of Internal Medicine (SNFMI)*
Association nationale des professionnels de santé exerçant en prison / National Association of Health Professionals Working in Prisons (APSEP)*
Société française d'anesthésie et de réanimation / French Society of Anesthesia and Intensive Care (SFAR)*
Société française de rhumatologie / French Society of Rheumatology (SFR)
Société française de pharmacologie thérapeutique / French Society of Therapeutic Pharmacology (SFPT)*
Collège national des gynécologues et obstétriciens français / National College of French Gynecologists and Obstetricians (CNGOF)
Collège national des sages-femmes de France / National College of Midwives of France (CNSF)
Collège national professionnel de rhumatologie / National Professional Council of Rheumatology*

* These organizations proposed one or more experts for this project.

Table S2. Detailed search strategy, including combinations of thesaurus and free-text terms

Type of study/Topic		Search period	Number of references found
	Terms used		
PAIN / OPIOIDS			
ACUTE PAIN / OPIOIDS			
Guidelines, consensus conferences		Janv. 09 Dec. 21	101
Step 1	(acute pain OR paroxysmal pain OR acute pains OR paroxysmal pains OR acute painful OR paroxysmal painful)/ti,ab OR (Acute Pain)/de		
AND			
Step 1	(acute pain OR paroxysmal pain OR acute pains OR paroxysmal pains OR acute painful OR paroxysmal painful)/ti,ab OR (Acute Pain)/de		
AND			
Step 2	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone)/ti,ab OR (Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de OR (opioid OR opioids OR opiate OR opiates)/ti,ab OR (Opiate Alkaloids OR Analgesics, Opioid OR Opiate OR Narcotic Analgesic Agent)/de		
AND			
Step 3	(consensus OR guidance OR guideline* OR position paper OR recommendation* OR statement*)/ti OR (health planning guidelines)/de OR (consensus development conference OR consensus development conference, NIH OR guideline OR practice guideline)/type		
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	198
Step 1 AND Step 2			
AND			
Step 4	(meta analys* OR metaanalys* OR systematic* overview* OR systematic* research* OR systematic* review* OR systematic* search*)/ti OR (metaanalysis OR systematic review)/de OR (meta-analysis OR systematic review)/type OR (Health Technol Assess)/so		
CHRONIC PAIN / OPIOIDS			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	206
Step 5	(chronic pain OR chronic pains OR chronic painful)/ti OR (Chronic Pain)/de		
AND			
Step 2 AND Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	263
Step 5 AND Step 2 AND Step 4			
CANCER-RELATED PAIN / OPIOIDS			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	60
Step 6	((cancer OR cancers OR oncology OR oncologic OR oncological OR neoplasm OR neoplasms OR metastase OR metastases) AND (pain OR painful OR pains))/ti OR (Cancer Pain)/de		
AND			
Step 2 AND Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	149
Step 6 AND Step 2 AND Step 4			
SUPPLEMENT / PAIN / OPIOIDS			

GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	139
Step 7	(pain)/ti OR (Pain)/de		
NOT			
Step 8	Step 1 OR Step 5 OR Step 6		
AND			
Step 2 AND Step 3			
PAIN / NON-OPIOID RECOMMENDATIONS			
ACUTE PAIN			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	120
(Step 1 NOT Step 2) AND Step 3			
CHRONIC PAIN			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	264
(Step 5 NOT Step 2) AND Step 3			
CANCER-RELATED PAIN			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	101
(Step 6 NOT Step 2) AND Step 3			
MISUSE			
EPIDEMIOLOGY			
FRANCE		Janv. 09 Dec. 21	42
Step 7	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (addict OR addicts OR addicted OR addiction OR addictions OR dependent OR dependence OR dependences OR dependency OR dependencies OR divert OR diverted OR diverting OR diversion OR diversions OR misuse OR misused OR misuses OR misusing OR problematic use OR use disorder OR use disorders OR abuse OR abuses OR abusing)/ti AND (epidemiology OR epidemiologic OR epidemiological OR incidence OR prevalence OR trends)/ti		
OR			
Step 8	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic Analgesic Agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Analgesic Agent Abuse OR Drug Abuse Pattern OR Drug Abuse OR Drug Craving OR Drug Dependence OR Drug Misuse OR Narcotic Dependence OR Narcotic-Related Disorders OR Prescription Drug Diversion OR Prescription Drug Misuse OR Prescription Drug Overuse OR Substance Abuse OR Substance-Related Disorders)/epidemiology/de		
OR			
Step 9	(Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence OR Morphine Addiction OR Opiate Addiction)/epidemiology/de		
AND			
Step 10	(France OR french)/ti,ab OR (France)/affiliation		
DEVELOPED COUNTRIES OTHER THAN THE USA AND CANADA		Janv. 09 Dec. 21	249
(Step 7 OR Step 8 OR Step 9)			
AND			
Step 11	(Europe* OR Austria OR Belgi* OR Russi* OR Finland OR finnish OR German* OR Great PRE/0 Britain OR british OR England OR english OR Ireland OR irish OR Scotland OR scottish OR Greece OR greek* OR Iceland OR Italy OR italian OR Netherlands OR dutch OR Portug* OR Scandinavia* OR Denmark OR danish OR Norway OR norvegian* OR		

	Sweden OR swedish OR Spain OR spanish OR Switzerland OR swiss OR Australia* OR New Zealand OR Japan*)/ti OR (European Union OR Europe OR European Union OR Europe OR Japan OR Australia OR New Zealand OR Japan OR Australia OR New Zealand)/de OR (Austria OR Belgium OR Russia OR Finland OR Deutschland OR England OR United Kingdom OR Ireland OR Eire OR Scotland OR Greece OR Iceland OR Italy OR Netherlands OR Portugal OR Denmark OR Norway OR Sweden OR Spain OR Switzerland OR Australia OR New Zealand OR Japan)/affiliation		
USA AND CANADA		Janv. 09 Dec. 21	144
(Step 7 OR Step 8 OR Step 9)			
AND			
Step 12	(Canada OR Canadian* OR United States OR USA OR America)/ti OR (North America)/de OR (Canada OR United States OR USA)/affiliation		
RISK FACTORS			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	6
Step 13	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (addict OR addicts OR addicted OR addiction OR addictions OR dependent OR dependence OR dependences OR dependency OR dependencies OR divert OR diverted OR diverting OR diversion OR diversions OR misuse OR misused OR misuses OR misusing OR problematic use OR use disorder OR use disorders OR abuse OR abuses OR abusing)/ti AND (risk factor*)/ti		
OR			
Step 14	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Substance-Related Disorders OR Narcotic-Related Disorders OR Drug Misuse OR Prescription Drug Misuse OR Prescription Drug Overuse OR drug dependence OR drug abuse pattern OR drug craving OR drug misuse OR narcotic dependence OR drug abuse OR analgesic agent abuse OR prescription drug diversion OR Substance Abuse)/de AND (Risk Factors OR Risk Factor)/de		
OR			
Step 15	(Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence OR Morphine Addiction OR Opiate Addiction)/de AND (Risk Factors OR Risk Factor)/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	14
(Step 13 OR Step 14 OR Step 15) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	75
Step 13 OR Step 14 OR Step 15			
AND			
Step 16	(random*)/ti,ab OR (Random Allocation)/de OR (randomized controlled trial)/type OR (single blind)/ti,ab OR (Single-Blind Method)/de OR (double blind)/ti,ab OR (Double-Blind Method)/de OR (clinical trial*)/ti,ab OR (Clinical Trial) OR Controlled Clinical Trial)/type OR (multicenter stud* OR multicentre stud*)/ti,ab OR (multicenter study)/type OR (cross over stud*)/ti,ab OR (Cross-Over Studies)/de OR (versus)/ti OR (comparative stud*)/ti,ab OR (Comparative Study)/type		
COHORT STUDIES		Janv. 09 Dec. 21	77

Step 13 OR Step 14 OR Step 15			
AND			
Step 17	(Cohort Studies)/de OR (cohort* OR follow up stud*)/ti OR (Follow-Up Studies)/de OR (prospective stud*)/ti OR (Prospective Studies)/de OR (longitudinal stud*)/ti OR (Longitudinal Studies)/de		
SCREENING			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	8
Step 18	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (addict OR addicts OR addicted OR addiction OR addictions OR dependent OR dependence OR dependences OR dependency OR dependencies OR divert OR diverted OR diverting OR diversion OR diversions OR misuse OR misused OR misuses OR misusing OR problematic use OR use disorder OR use disorders OR abuse OR abuses OR abusing)/ti AND (screening OR screen OR test OR tests OR testing OR detect OR detects OR detection OR detecting OR investigate OR investigates OR investigation OR investigating OR marker OR markers OR biomarker OR biomarkers)/ti		
OR			
Step 19	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Substance-Related Disorders OR Narcotic-Related Disorders OR Drug Misuse OR Prescription Drug Misuse OR Prescription Drug Overuse OR Drug Dependence OR Drug Abuse Pattern OR Drug Craving OR Drug Misuse OR Narcotic Dependence OR Drug Abuse OR Analgesic Agent Abuse OR Prescription Drug Diversion OR Substance Abuse)/de AND (Mass Screening OR Diagnostic Screening Programs OR Direct-To-Consumer Screening and Testing OR Substance Abuse Detection OR Screening)/de		
OR			
Step 20	(Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence OR Morphine Addiction OR Opiate Addiction)/de AND (Mass Screening OR Diagnostic Screening Programs OR Direct-To-Consumer Screening and Testing OR Substance Abuse Detection OR Screening)/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	8
(Step 18 OR Step 19 OR Step 20) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	66
(Step 18 OR Step 19 OR Step 20) AND Step 16			
COHORT STUDIES		Janv. 09 Dec. 21	65
(Step 18 OR Step 19 OR Step 20) AND Step 17			
PREVENTION			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	44
Step 21	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (addict OR addicts OR addicted OR addiction OR addictions OR dependent OR dependence OR dependences OR dependency OR dependencies OR		

	divert OR diverted OR diverting OR diversion OR diversions OR misuse OR misused OR misuses OR misusing OR problematic use OR use disorder OR use disorders OR abuse OR abuses OR abusing)/ti AND (prevent OR prevents OR preventing OR prevention OR keep from OR keeps from OR keeping from OR avoid OR avoids OR avoiding)/ti		
OR			
Step 22	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Substance-Related Disorders OR Narcotic-Related Disorders OR Drug Misuse OR Prescription Drug Misuse OR Prescription Drug Overuse OR Drug Dependence OR Drug Abuse Pattern OR Drug Craving OR Drug Misuse OR Narcotic Dependence OR Drug Abuse OR Analgesic Agent Abuse OR Prescription Drug Diversion OR Substance Abuse)/de AND (Primary Prevention OR Secondary Prevention OR Tertiary Prevention OR Quaternary Prevention OR Protective Factors OR Preventive Medicine OR Preventive Health Service)/de		
OR			
Step 23	(Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence OR Morphine Addiction OR Opiate Addiction)/de AND (Primary Prevention OR Secondary Prevention OR Tertiary Prevention OR Quaternary Prevention OR Protective Factors OR Preventive Medicine OR Preventive Health Service)/de		
OR			
Step 24	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Substance-Related Disorders OR Narcotic-Related Disorders OR Drug Misuse OR Prescription Drug Misuse OR Prescription Drug Overuse)/prevention & control/de OR (Drug Dependence OR Drug Craving OR Drug Misuse OR Narcotic Dependence OR Drug Abuse OR Analgesic Agent Abuse OR Prescription Drug Diversion OR Substance Abuse)/prevention/de		
OR			
Step 25	(Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence) prevention & control/de OR (Morphine Addiction OR Opiate Addiction)/prevention/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	43
(Step 21 OR Step 22 OR Step 23 OR Step 24 OR Step 25) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	130
(Step 21 OR Step 22 OR Step 23 OR Step 24 OR Step 25) AND Step 16			
COHORT STUDIES		Janv. 09 Dec. 21	92
(Step 21 OR Step 22 OR Step 23 OR Step 24 OR Step 25) AND Step 17			
TREATMENT			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	114
Step 26	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (addict OR addicts OR addicted OR addiction OR addictions OR dependent OR dependence OR dependences OR dependency OR dependencies OR		

	divert OR diverted OR diverting OR diversion OR diversions OR misuse OR misused OR misuses OR misusing OR problematic use OR use disorder OR use disorders OR abuse OR abuses OR abusing)/ti AND (treatment)/ti		
OR			
Step 27			
Step 28			
Step 29	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Substance-Related Disorders OR Narcotic-Related Disorders OR Drug Misuse OR Prescription Drug Misuse OR Prescription Drug Overuse OR Drug Dependence OR Drug Abuse Pattern OR Drug Craving OR Drug Misuse OR Narcotic Dependence OR Drug Abuse OR Analgesic Agent Abuse OR Prescription Drug Diversion OR Substance Abuse)/de AND (Buprenorphine/therapeutic use OR Methadone/therapeutic use OR Substance Abuse Treatment Centers)/de OR (Opioid-Related Disorders OR Morphine Dependence OR Opium Dependence)/de AND (Buprenorphine/therapeutic use OR Methadone/therapeutic use OR Substance Abuse Treatment Centers)/de OR (codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone)/de AND (Substance-Related Disorders/drug therapy OR Substance-Related Disorders/rehabilitation OR Substance-Related Disorders/therapy OR Substance-Related Disorders/diet therapy OR Narcotic-Related Disorders/therapy OR Narcotic-Related Disorders/drug therapy OR Narcotic-Related Disorders/rehabilitation OR Narcotic-Related Disorders/diet therapy)/de		
OR			
Step 30	(opioid-related disorders/therapy OR opioid-related disorders/drug therapy)/de		
OR			
Step 31	(Opiate Substitution Treatment)/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	238
(Step 26 OR Step 27 OR Step 28 OR Step 29 OR Step 30 OR Step 31) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	365
(Step 26 OR Step 27 OR Step 28 OR Step 29 OR Step 30 OR Step 31) AND Step 16			
COHORT STUDIES		Janv. 09 Dec. 21	258
(Step 26 OR Step 27 OR Step 28 OR Step 29 OR Step 30 OR Step 31) AND Step 17			
OVERDOSE			
EPIDEMIOLOGY			
FRANCE		Janv. 09 Dec. 21	10
Step 32	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (overdose OR overdoses OR lethal OR fatal OR mortal OR mortality OR die OR dies OR died OR dying OR death OR deaths OR dead OR deadly OR victim OR victims OR succumb OR succumbs OR succumbing OR		

	succumbed OR decimate OR decimates OR decimating OR decimated OR wipe out OR wipes out OR wiped out OR kill OR kills OR killed OR killing OR poisoning)/ti AND (epidemiology OR epidemiologic OR epidemiological OR incidence OR prevalence OR trends OR rate OR rates)/ti		
OR			
Step 33	(Codeine OR Tramadol OR Morphine OR Nalbuphine OR Hydromorphone OR Tapentadol OR Oxycodone OR Fentanyl OR Meperidine OR Buprenorphine OR Methadone OR codeine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR buprenorphine OR methadone OR Opiate Alkaloids OR Analgesics, Opioid OR Opiate OR Narcotic analgesic agent)/de AND ((Drug Overdose/epidemiology OR Death/epidemiology OR Drug Fatality/epidemiology) OR (Substance-Related Disorders/mortality AND Substance-Related Disorders/epidemiology) OR (Narcotic-Related Disorders/mortality AND Narcotic-Related Disorders/epidemiology) OR (Drug Misuse/mortality AND Drug Misuse/epidemiology) OR (Prescription Drug Misuse/mortality AND Prescription Drug Misuse/epidemiology) OR (Prescription Drug Overuse/mortality AND Prescription Drug Overuse/epidemiology))		
OR			
Step 34	((Opioid-Related Disorders/mortality) AND (Opioid-Related Disorders/epidemiology))/de OR ((Morphine Dependence/mortality) AND (Morphine Dependence/epidemiology))/de OR (Opium Dependence/mortality) AND (Opium Dependence/epidemiology))/de		
AND			
Step 10			
DEVELOPED COUNTRIES OTHER THAN THE USA AND CANADA		Janv. 09 Dec. 21	151
(Step 32 OR Step 33 OR Step 34) AND Step 11			
USA AND CANADA		Janv. 09 Dec. 21	175
(Step 32 OR Step 33 OR Step 34) AND Step 12			
RISK FACTORS			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	1
Step 35	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (overdose OR overdoses OR lethal OR fatal OR mortal OR mortality OR die OR dies OR died OR dying OR death OR deaths OR dead OR deadly OR victim OR victims OR succumb OR succumbs OR succumbing OR succumbed OR decimate OR decimates OR decimating OR decimated OR wipe out OR wipes out OR wiped out OR kill OR kills OR killed OR killing OR poisoning)/ti AND (predict OR predicts OR predictor OR predictors OR prediction OR predicting OR risk factor OR risk factors OR pattern OR patterns)/ti		
OR			
Step 36	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (risk overdose OR risk overdoses OR risk lethal OR risk fatal OR risk mortal OR risk mortality OR risk die OR risk dies OR risk died OR risk dying OR risk death OR risk deaths OR risk dead OR risk deadly OR risk victim OR risk victims OR risk succumb OR risk succumbs OR risk succumbing OR risk succumbed OR risk decimate OR risk decimates OR risk decimating OR risk decimated OR risk wipe out OR risk wipes out OR		

	risk wiped out OR risk kill OR risk kills OR risk killed OR risk killing OR risk poisoning)/ti		
OR			
Step 37	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Drug Overdose/etiology OR Death/etiology OR (Substance-Related Disorders/mortality AND Substance-Related Disorders/etiology) OR (Narcotic-Related Disorders/mortality AND Narcotic-Related Disorders/etiology) OR (Drug Misuse/mortality AND Drug Misuse/etiology) OR (Prescription Drug Misuse/mortality AND Prescription Drug Misuse/etiology) OR (Prescription Drug Overuse/mortality AND Prescription Drug Overuse/etiology) OR drug fatality/etiology)/de		
OR			
Step 38	((Opioid-Related Disorders/mortality AND Opioid-Related Disorders/etiology) OR (Morphine Dependence/mortality AND Morphine Dependence/etiology) OR (Opium Dependence/mortality AND Opium Dependence/etiology))/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	6
(Step 35 OR Step 36 OR Step 37 OR Step 38) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	30
(Step 35 OR Step 36 OR Step 37 OR Step 38) AND Step 16			
COHORT STUDIES		Janv. 09 Dec. 21	78
(Step 35 OR Step 36 OR Step 37 OR Step 38) AND Step 17			
PREVENTION			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	12
Step 39	(codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (overdose OR overdoses OR lethal OR fatal OR mortal OR mortality OR die OR dies OR died OR dying OR death OR deaths OR dead OR deadly OR victim OR victims OR succumb OR succumbs OR succumbing OR succumbed OR decimate OR decimates OR decimating OR decimated OR wipe out OR wipes out OR wiped out OR kill OR kills OR killed OR killing OR poisoning)/ti AND (prevent OR prevents OR preventing OR prevention OR keep from OR keeps from OR keeping from OR avoid OR avoids OR avoiding OR reverse OR reverses OR reversal)/ti		
OR			
Step 40	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Drug Overdose OR Death OR Mortality OR Substance-Related Disorders/mortality OR Narcotic-Related Disorders/mortality OR Drug Misuse/mortality OR Prescription Drug Misuse/mortality OR Prescription Drug Overuse/mortality OR Drug Overdose OR drug fatality OR mortality)/de AND (Primary Prevention OR Secondary Prevention OR Tertiary Prevention OR Quaternary Prevention OR Preventive Medicine OR preventive health service)/de		
OR			

Step 41	(Opioid-Related Disorders/mortality OR Morphine Dependence/mortality OR Opium Dependence/mortality)/de AND (Primary Prevention OR Secondary Prevention OR Tertiary Prevention OR Quaternary Prevention)/de		
OR			
Step 42	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Drug Overdose/prevention & control OR Drug Overdose/prevention)/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	18
(Step 39 OR Step 40 OR Step 41 OR Step 42) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	61
(Step 39 OR Step 40 OR Step 41 OR Step 42) AND Step 16			
COHORT STUDIES		Janv. 09 Dec. 21	51
(Step 39 OR Step 40 OR Step 41 OR Step 42) AND Step 17			
TREATMENT			
GUIDELINES, CONSENSUS CONFERENCES		Janv. 09 Dec. 21	16
Step 43	(Codeine OR methylmorphine OR dihydrocodeine OR tramadol OR morphine OR nalbuphine OR hydromorphone OR tapentadol OR oxycodone OR fentanyl OR pethidine OR meperidine OR demerol OR buprenorphine OR methadone OR opioid OR opioids OR opiate OR opiates)/ti AND (overdose OR overdoses OR poisoning OR poisonings)/ti AND (treat OR treats OR treating OR treatment OR treatments OR therapy OR therapies OR pharmacotherapy OR pharmacotherapies OR therapeutic OR therapeutics OR therapeutical OR manage OR manages OR managing OR management OR medicate OR medicates OR medication OR medications OR caring OR address OR addresses OR addressing OR reduce OR reduces OR reducing OR reduction OR tackle OR tackles OR tackling OR tackled OR mitigate OR mitigates OR mitigating OR naloxone)/ti		
OR			
Step 44	(Codeine OR Tramadol OR Morphine OR Nalbuphine OR Hydromorphone OR Tapentadol OR Oxycodone OR Fentanyl OR Meperidine OR Buprenorphine OR Methadone OR Opiate Alkaloids OR Analgesics, Opioid)/de AND (Drug Overdose)/de AND (Naloxone/therapeutic use)/de		
OR			
Step 45	(Analgesics, Opioid OR Buprenorphine OR Codeine OR Dihydrocodeine OR Fentanyl OR Hydromorphone OR Meperidine OR Methadone OR Morphine OR Nalbuphine OR Narcotic analgesic agent OR Opiate OR Opiate Alkaloids OR Oxycodone OR Pethidine OR Tapentadol OR Tramadol)/de AND (Drug Overdose/diet therapy OR Drug Overdose/drug therapy OR Drug Overdose/therapy OR Drug Overdose/rehabilitation OR Drug Overdose/rehabilitation OR Drug Overdose/therapy OR Drug Overdose/drug therapy OR Drug Overdose/disease management)/de		
AND			
Step 3			
META-ANALYSES, SYSTEMATIC REVIEWS		Janv. 09 Dec. 21	42
(Step 43 OR Step 44 OR Step 45) AND Step 4			
CLINICAL TRIALS		Janv. 09 Dec. 21	110
(Step 43 OR Step 44 OR Step 45) AND Step 16			

COHORT STUDIES	Janv. 09	164
(Step 43 OR Step 44 OR Step 45) AND Step 17	Dec. 21	

de: descriptor; ti: title; ab: abstract; *: explode generic term; type: publication type; so: journal name

Table S3. Websites consulted

Académie nationale de médecine / French National Academy of Medicine
Académie nationale de pharmacie / French National Academy of Pharmacy
Agence nationale de sécurité du médicament et des produits de santé (ANSM) / French National Agency for Medicines and Health Products Safety (ANSM)
Assemblée nationale / French National Assembly
Assurance maladie / French National Health Insurance
Bibliothèque médicale Lemanissier / Lemanissier Medical Library
Catalogue et index des sites médicaux francophones (CISMeF) / Catalogue and Index of French-language Medical Sites (CISMeF)
Direction de la Recherche, des Études, de l'Évaluation et des Statistiques (DREES) / Directorate for Research, Studies, Evaluation and Statistics (DREES)
Fédération Addiction / Addiction Federation
Haute Autorité de santé (HAS) / French National Authority for Health (HAS)
Institut national de la santé et de la recherche médicale (Inserm) / National Institute of Health and Medical Research (Inserm). Collective Expert Reviews
Ministère de la Santé / French Ministry of Health
Mission interministérielle de Lutte contre les drogues et les conduites addictives (MILDECA) / Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA)
Observatoire du médicament, des dispositifs médicaux et de l'innovation thérapeutique (OMéDIT) / Observatory of Medicines, Medical Devices and Therapeutic Innovation (OMéDIT)
Observatoire français des drogues et des toxicomanies (OFDT) / French Monitoring Centre for Drugs and Drug Addiction (OFDT)
Observatoire français des médicaments antalgiques (Ofma) / French Observatory of Analgesic Medicines (Ofma)
Réseau de prévention des addictions (RESPADD) / Network for Addiction Prevention (RESPADD)
Réseau français d'addictovigilance / French Addictovigilance Network
Société française d'étude et de traitement de la douleur (SFETD) / French Society for the Study and Treatment of Pain (SFETD)
Centre fédéral d'expertise des soins de santé (KCE) / Belgian Health Care Knowledge Centre (KCE)
Office fédéral de la santé publique (OFSP) / Swiss Federal Office of Public Health (OFSP)
Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) / German Institute for Medical Documentation and Information (DIMDI)
European Medicines Agency (EMA)
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Conseil scientifique domaine de la santé du Luxembourg / Luxembourg Health Scientific Council
Norwegian Knowledge Centre for the Health Services
Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
BMJ Best Practice
British Association for Psychopharmacology (BAP)
British Medical Association (BMA)
British Pain Society
National Institute for Health and Care Excellence (NICE)
Public Health England
Royal College of General Practitioners (RCGP)
Royal College of Psychiatrists (RCPsych)
Scottish Intercollegiate Guidelines Network (SIGN)
UK Advisory Council on the Misuse of Drugs
UK Department of Health (DoH)
UK Medicines and Healthcare products Regulatory Agency (MHRA)
UK National Institute for Health Research (NIHR)
UK National Treatment Agency for Substance Misuse (NTA)
Agence de la santé publique du Canada / Public Health Agency of Canada

Alberta College of Family Physicians
British Columbia Centre on Substance Use
Canada Centre for Addiction and Mental Health (CAMH)
Canadian Agency for Drugs and Technologies in Health (CADTH)
Canadian Institutes of Health Research (CIHR), Canadian Research Initiative in Substance Misuse
Canadian Society of Addiction Medicine
Collège des médecins du Québec (CMQ) / College of Physicians of Quebec (CMQ)
College of Physicians & Surgeons of Alberta (CPSA)
College of Physicians and Surgeons of British Columbia
College of Physicians and Surgeons of Saskatchewan
College of Physicians and Surgeons of Newfoundland and Labrador
Gouvernement du Canada / Government of Canada
Guidelines and Protocols Advisory Committee, British Columbia
Health Quality Ontario (HQP)
Institut national de santé publique du Québec (INSPQ) / Quebec National Institute of Public Health (INSPQ)
Institut national d'excellence en santé et en services sociaux du Québec (INESSS) / Quebec National Institute of Excellence in Health and Social Services (INESSS)
Ministère de la Santé et des Services sociaux du Québec (MSSS) / Quebec Ministry of Health and Social Services (MSSS)
Registered Nurses' Association of Ontario (RNAO)
Agency for Healthcare Research and Quality (AHRQ)
American College of Physicians
American Pain Society
American Psychological Association (APA)
American Society for Pain Management Nursing
American Society of Addiction Medicine (ASAM)
Center for Drug Evaluation and Research (CDER)
Centers for Disease Control and Prevention (CDC)
Institute for Clinical and Economic Review (ICER)
Institute for Clinical Systems Improvement (ICSI)
Kaiser Permanente
Michigan Quality Improvement Consortium (MQIC)
National Academies of Sciences
The Commonwealth Fund
US Department of Health and Human Services (HHS)
US Department of Veterans Affairs
US Drug Enforcement Administration (DEA)
US Food and Drug Administration (FDA)
US Government Accountability Office (GAO)
US National Institute on Drug Abuse (NIDA)
US National Institutes of Health (NIH)
US Preventive Services Task Force (USPSTF)
US Substance Abuse and Mental Health Services Administration (SAMHSA)
Australian Clinical Practice Guidelines
National Health and Medical Research Council (NHMRC)
New Zealand Ministry of Health
Organisation for Economic Co-operation and Development (OECD)
World Health Organization (WHO)

Table S4. Members of the Working Group

Name	Specialty / Profession	City	Role in the Working Group
Prof. Nicolas Authier	Psychiatrist, Pharmacologist, Addiction Specialist	Clermont-Ferrand	Chair of the Working Group
Dr Célian Bertin	Psychiatrist, Pharmacologist, Addiction Specialist	Clermont-Ferrand	Project Lead
Dr Mathieu Chappuy	Pharmacist, Addiction Specialist	Lyon	Project Lead
Dr Julie Dupouy	General Practitioner	Toulouse	Project Lead
Dr Nathalie Michenot	Palliative Care Physician	Le Chesnay	Project Lead
Dr Sidonie Verdier	Palliative Care Physician	Le Chesnay	Project Lead
Dr Anne-Priscille Trouvin	Rheumatologist, Pain Specialist	Paris	Project Lead
Dr Marie Augé-Caumon	Community Pharmacist (retired)	Paris	Member
Ms Julie Berard-Mistiaen	Nurse	Villejuif	Member
Dr Lucas Beurton-Couraud	General Practitioner	Pleyben	Member
Dr Florian Boureau	Orthopedic Surgeon	Cavaillon	Member
Mr Albert Caporossi	Patient Representative	Paris	Member
Dr Jean-Michel Delile	Psychiatrist	Bordeaux	Member
Ms Nathalie Deparis	Patient Representative	Montreuil	Member
Dr Vincent Dubarry	Community Pharmacist	Bordeaux	Member
Dr Louise-Adelaïde Jakubiec	Psychiatrist, Addiction Specialist	Bordeaux	Member
Dr Isabelle Jolivet	Hospital Pharmacist	Paris	Member
Dr Virginie Lvovschi	Emergency Physician	Rouen	Member
Dr Christian Michel	General Practitioner, Addiction Specialist	Strasbourg	Member
Ms Émilie Monzon	ANSM	Saint-Denis	Member
Mr Fabrice Olivet	Patient Representative	Paris	Member
Dr Philippe Poulain	Anesthesiologist-Intensivist	Tarbes	Member
Dr Sophie Pouplin	Rheumatologist, Pain Specialist	Rouen	Member
Ms Nathalie Richard	ANSM	Saint-Denis	Member
Dr Bruno Roméo	Psychiatrist	Villejuif	Member
Dr Sylvie Rostaing	Anesthesiologist, Pain Specialist	Avignon	Member
Ms Manon Schwager	INCa	Boulogne-Billancourt	Member
Dr Florence Vorspan	Psychiatrist, Addiction Specialist	Paris	Member

Table S5. Members of the Reading Group

Name	Specialty / Profession	City	Role in the Reading Group
Pr Frédéric Aubrun	Anesthesiologist, Intensivist	Lyon	Member
Mme Sandrine Avignon	Nurse	Paris	Member
Dr Florian Bailly	Rheumatologist, Pain Physician	Paris	Member
Dr Cécile Bernard	Pain and Palliative Care Physician	Marseille	Member
Dr Mario Blaise	Psychiatrist, Addiction Specialist	Paris	Member
Dr Anna Bouchara	Emergency Physician	Aulnay-sous-Bois	Member
Mme Maria Carlos	Nurse	Paris	Member
Dr Philippe Castera	General Practitioner, Addiction Specialist	Bordeaux	Member
Dr Bérangère Caumes	Emergency Physician	Rouen	Member
Dr Christel Conso	Orthopedic Surgeon	Paris	Member
Dr Rodrigue Deleens	Pain Physician	Rouen	Member
Dr Thierry Delorme	Pain Physician	Angers	Member
Pr Maurice Dematteis	Neurologist, Pharmacologist, Addiction Specialist	Grenoble	Member
Pr Antoine Dupuis	Hospital Pharmacist	Poitiers	Member
Dr Françoise Etchebar	Addiction Specialist	Pau	Member
Dr Adrien Evin	Palliative Care and Pain Physician	Nantes	Member
Pr Dominique Fletcher	Anesthesiologist, Intensivist	Boulogne-Billancourt	Member
M. Maxence Gal	Nurse	Sanary-sur-Mer	Member
Pr Michel Galinski	Emergency Physician	Bordeaux	Member
M. Miguel Gorsse-Velazquez	Health System User	Paris	Member
M. Jean-Maxence Granier	Health System User	Paris	Member
Dr Virginie Guastella	Pain and Palliative Care Physician	Clermont-Ferrand	Member
Pr Thomas Hanslik	Internist	Boulogne-Billancourt	Member
Dr François Jedryka	Pain Physician	Nîmes	Member
M. Marko Kalk	Health System User	Strasbourg	Member
Dr Philippe Lambert	General Practitioner	Montpellier	Member
Mme Estelle Ledon	Pediatric Nurse	Besançon	Member
Dr Antoine Lemaire	Palliative Care and Pain Physician	Valenciennes	Member
Dr Fabien Lemoel	Emergency Physician	Nice	Member
Dr Joël L'Hermite	Anesthesiologist, Intensivist	Nîmes	Member
Dr Axel Maurice-Szamburski	Anesthesiologist, Intensivist	Marseille	Member
Dr Fadi Meroueh	Addiction Specialist, Prison Physician	Montpellier	Member
Dr Pascal Millet	Anesthesiologist, Addiction Specialist, Palliative Care, Prison Physician, GP (retired)	Vyans-le-Val	Member
Dr Xavier Moisset	Neurologist	Clermont-Ferrand	Member
Dr Géraldine Muller	Internist	Dijon	Member
Dr Virginie Paillou	Addiction Specialist	Bordeaux	Member
Dr Karine Pansiot	Community Pharmacist	Dijon	Member
Dr Gilles Pasquier	Orthopedic Surgeon	Lille	Member
Dr Ségolène Perruchio	Palliative Care and Pain Physician	Puteaux	Member
Pr Gisèle Pickering	Pharmacologist	Clermont-Ferrand	Member

Dr Guillaume Racle	Community Pharmacist	Paris	Member
Mme Émilie Ria	Pediatric Nurse	Nancy	Member
Dr Stéphane Robinet	Pharmacist, Addiction Specialist	Strasbourg	Member
Dr Romain Sicot	Psychiatrist, Addiction Specialist	Paris	Member
Dr Alexandre Theissen	Anesthesiologist, Intensivist	Monaco	Member
Dr Stéphanie Trager	Oncologist	Puteaux	Member
Pr Patrick Tropicano	Orthopedic Surgeon	Marseille	Member
Pr Pascale Vergne-Salle	Rheumatologist, Pain Physician	Limoges	Member
Pr Caroline Victorri-Vigneau	Pharmacologist	Nantes	Member
Mme Malak Abou-Taam	ANSM	Saint-Denis	Consulted
Mme Marianne Duperray	INCa	Boulogne-Billancourt	Consulted
Dr Ruth Gozlan	MILDECA	Paris	Consulted
Mme Valérie Izard	HAS	Saint-Denis	Consulted
Mme Sarah Koné	HAS	Saint-Denis	Consulted
Mme Amélie Prigent	HAS	Saint-Denis	Consulted
Mme Chloé Rebstock	HAS	Saint-Denis	Consulted